Surgical Innovations Group hails ‘resilient performance in a challenging year’ as losses narrow
Yorkshire-based Surgical Innovations Group has seen its losses narrow, with the company hailing a “resilient performance in what was a challenging year”.
The company posted a pre-tax loss of £944,000 for the year ending December 31, down from £2m a year prior.
But the firm posted an adjusted EBITDA loss for 2025 of £0.4m, down from profit of £0.05m in 2024.
It came as the company saw sales in its overall Surgical Innovations branded products decreased eight per cent to £5.9m.
The firm said this was driven by tariff headwinds in the USA and structural sales challenges with its partner in India
Speaking on the results, chairman of Surgical Innovations, Roy Davis, said: "The company delivered a resilient performance in what was a challenging year.
“With a positive start to 2026, a focus on the basics and several strategic initiatives underway, the company is better positioned for future growth and long-term success.
“Our focus on sustainability-led market expansion, targeted distribution partnerships, and innovative product additions will continue to strengthen the company's competitive position.
“Concurrently, ongoing cost-optimisation initiatives are enhancing profitability and supporting sustainable operations.”
Surgical Innovations Group specialises in the design, manufacture, sale and distribution of medical products, primarily for use in minimally invasive surgery.